Residency · Residency · Neurology

Restless Legs Syndrome and Sleep-Related Movement Disorders

Introduction

Sleep-related movement disorders are characterized by simple, stereotyped movements that disturb sleep or its onset. Restless legs syndrome (RLS) is the most common and clinically significant of these disorders, affecting 5-10% of the general population. Understanding the pathophysiology and treatment of RLS and related conditions is essential for the practicing neurologist.

Restless Legs Syndrome (Willis-Ekbom Disease)

Diagnostic Criteria (IRLSSG)

All five essential criteria must be met for diagnosis. First, there must be an urge to move the legs, usually accompanied by or resulting from uncomfortable sensations described as crawling, pulling, aching, tingling, or "indescribable." Second, symptoms begin or worsen during periods of rest or inactivity. Third, symptoms are partially or totally relieved by movement such as walking or stretching for as long as the activity continues. Fourth, symptoms occur exclusively or predominantly in the evening or at night. Fifth, symptoms are not solely accounted for by another medical or behavioral condition, meaning mimics must be excluded.

Supportive Features

Supportive features include a family history of RLS (first-degree relatives are affected in 40-60% of cases), a positive response to dopaminergic therapy, and periodic limb movements during sleep (PLMS) on polysomnography, which are present in more than 80% of RLS patients.

Pathophysiology

Brain iron deficiency is central to the pathophysiology, with reduced iron stores in the substantia nigra even when serum ferritin is normal. Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. The A2 hypothesis of dopaminergic dysfunction proposes that iron deficiency leads to dopaminergic hyperactivity followed by receptor downregulation. Genome-wide association studies have identified risk loci including BTBD9, MEIS1, MAP2K5, and PTPRD. Circadian modulation explains why symptoms peak in the evening, correlating with the circadian nadir of dopaminergic activity and iron availability in the brain.

Secondary Causes of RLS

Iron deficiency with serum ferritin less than 75 mcg/L, even without anemia, can cause or worsen RLS. Chronic kidney disease and end-stage renal disease carry a prevalence of 20-60%. Pregnancy, especially the third trimester, is a common trigger though symptoms usually resolve postpartum. Peripheral neuropathy, particularly small fiber neuropathy, is associated with RLS. Medications that worsen RLS include antidopaminergic agents (metoclopramide, antipsychotics), antihistamines, SSRIs, and SNRIs.

Treatment

Iron Supplementation

Serum ferritin and transferrin saturation should be checked in all RLS patients. Oral iron supplementation is indicated if ferritin is less than 75 mcg/L, with ferrous sulfate 325 mg given with vitamin C on an empty stomach every other day. Intravenous iron with ferric carboxymaltose 1000 mg is appropriate for ferritin less than 100 mcg/L with inadequate oral response or intolerance.

Pharmacotherapy

Alpha-2-delta calcium channel ligands are now first-line therapy. Gabapentin enacarbil (300-600 mg) and pregabalin (75-300 mg at bedtime) are effective without the risk of augmentation. Dopamine agonists including pramipexole (0.125-0.5 mg), ropinirole (0.25-4 mg), and rotigotine transdermal patch (1-3 mg) are effective but carry significant risk of augmentation. Low-dose opioids such as oxycodone or prolonged-release oxycodone/naloxone are reserved for refractory cases. Clonazepam may improve sleep quality but does not address the core RLS urge.

Augmentation

Augmentation is the most important long-term complication of dopaminergic therapy for RLS. It is defined as worsening of RLS symptoms despite stable or increasing dopaminergic dose. Features include earlier onset of symptoms in the day, spread to the arms or trunk, shorter latency to symptom onset at rest, and shorter duration of medication effect. Management requires slowly tapering and discontinuing the dopamine agonist, switching to an alpha-2-delta ligand, ensuring iron stores are replete, and considering low-dose opioid for the transition period.

Periodic Limb Movement Disorder (PLMD)

Periodic limb movement disorder involves repetitive, stereotyped dorsiflexion of the ankle and extension of the great toe during sleep, resembling a triple flexion response. Movements occur in clusters with a periodicity of 20-40 seconds. The periodic limb movement index (PLMI) counts PLMs per hour of sleep, with greater than 15 per hour in adults considered abnormal. A diagnosis of PLMD requires PLMS plus clinical sleep disturbance or daytime impairment not explained by another disorder. PLMS are common in RLS (greater than 80%) but also occur in OSA, narcolepsy, RBD, and aging. Treatment is similar to RLS when clinically significant, with alpha-2-delta ligands preferred.

Sleep-Related Leg Cramps

Sleep-related leg cramps are sudden, painful, involuntary muscle contractions typically affecting the calf or foot during sleep. They are very common, especially in older adults and pregnant women. They are distinguished from RLS by being painful, focal, and brief (seconds to minutes), with palpable muscle hardness that is relieved by stretching the affected muscle. Treatment includes stretching exercises before bed and magnesium supplementation (with limited evidence); quinine is no longer recommended due to toxicity risk.

Sleep-Related Bruxism

Sleep-related bruxism involves repetitive jaw clenching and tooth grinding during sleep. It can cause dental damage, temporomandibular joint pain, headache, and sleep disruption. Diagnosis is based on clinical history and dental examination, with PSG showing rhythmic masticatory muscle activity. Treatment options include dental splints or mouth guards, stress management, and botulinum toxin injections for severe cases.

Rhythmic Movement Disorder

Rhythmic movement disorder consists of repetitive, stereotyped rocking, head banging, or body rolling at sleep onset. It is common in infants and typically resolves by age 5. Persistence into adulthood is rare and may be associated with neurodevelopmental disorders. Treatment involves environmental safety measures and behavioral therapy.

Clinical Pearls

Serum ferritin should always be checked in patients with RLS, as iron repletion to ferritin greater than 75 mcg/L is a foundational treatment that should precede or accompany pharmacotherapy. Alpha-2-delta ligands (gabapentin enacarbil, pregabalin) are now recommended as first-line over dopamine agonists due to the risk of augmentation with long-term dopaminergic therapy. Augmentation is the most common cause of treatment failure in RLS and should be suspected when previously controlled symptoms worsen, occur earlier in the day, or spread to new body parts. PLMS are a polysomnographic finding, not a diagnosis; clinical significance depends on whether they cause sleep disruption or daytime impairment. Many commonly prescribed medications including SSRIs, antihistamines, and antipsychotics can trigger or worsen RLS, making medication list review essential.

References

1. Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated IRLSSG consensus criteria. Sleep Med. 2014;15(8):860-873.
2. Silber MH, Buchfuhrer MJ, Earley CJ, et al. The management of restless legs syndrome: an updated algorithm. Mayo Clin Proc. 2021;96(7):1921-1937.
3. Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children. Sleep Med. 2018;41:27-44.
4. Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation. Sleep Med. 2016;21:1-11.

Read this lecture as Markdown